Skip to content

Effect of a mouthwash containing Cinnamomum zeylanicum Blume (Cinnamon) for treatment of oral candidiasis

Clinical evaluation of a mouthwash based on Cinnamomum zeylanicum Blume (Cinnamon) on Candida species in patients with denture stomatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-33s6x5
Enrollment
Unknown
Registered
2019-06-07
Start date
2018-01-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral candidiasis associated with the use of removable dental prosthesis.

Interventions

Participants with a confirmed diagnosis of prosthetic stomatitis were divided into two groups: 1) Experimental: 18 subjects received a treatment kit containing a sealed vial (450 mL) of mouthwash, a m
2) Control: 18 subjects received a treatment kit, which contained a sealed vial (450 mL) of mouthwash, one dose cup (10 mL), one spray (150 mL) containing nystatin applied under the same conditions ap
Drug

Sponsors

Universidade Federal da Paraíba
Lead Sponsor
Universidade Federal da Paraíba
Collaborator

Eligibility

Age
No minimum to 70 Months

Inclusion criteria

Inclusion criteria: Individuals aged 40 to 70 years with oral candidiasis and who wore removable dentures.

Exclusion criteria

Exclusion criteria: Individuals who had undergone topical and/or systemic antimicrobial treatment or were sensitive to C. zeylanicum EO or nystatin were excluded.

Design outcomes

Primary

MeasureTime frame
Presentation of the expected outcome: improvement of clinical aspects (coloration, texture, presence of pseudomembrane and edema) of the palatal mucosa, verified from clinical examination by visual inspection and palpation before and after the study. Data collected before and after 15 days of use of the experimental and control products. According to the parameter defined for the sample calculation, a cure rate of 80% is expected.;Presentation of observed outcome: From the results obtained and statistical analysis performed, there was a significant clinical improvement (p = 0.0139, Wilcoxon test), with a 55.6% cure rate.

Secondary

MeasureTime frame
Presentation of expected secondary outcome: decrease in the number of colony forming units of Candida spp., Verified from mycological examination of the affected mucosa, observed before and after use of the experimental product.;Presentation of the secondary endpoint observed: No change in the number of colony forming units of Candida spp., Verified from mycological examination of the affected mucosa, observed before and after use of the experimental product.

Countries

Brazil

Contacts

Public ContactRicardo;Ricardo Castro;Castro

Universidade Federal da Paraíba;Universidade Federal da Paraíba

rcastro@ccs.ufpb.br;rcastro@ccs.ufpb.br+5508332167742;08332167742

Outcome results

None listed

Source: REBEC (via WHO ICTRP)